Tokyo, December 7: N.K.Curex Co., Ltd. ( Minato-ku, Tokyo; president: Hidekazu Kurami ) and KAKEN PHARMACEUTICAL CO., LTD. ( Bunkyo-ku, Tokyo; president: Shiro Inui ) have come to an agreement for the marketing of the drug for diabetic neuropathy Aldos ( generic name: fidarestat; development code number: SNK-860 ).
The drug was codeveloped by N.K.Curex and Sanwa Kagaku Kenkyusho Co., Ltd. An NDA was submitted to Koseisho by the two companies on September 25, 2000. N.K.Curex and KAKEN have been discussing its domestic marketing, and have come to an agreement under which KAKEN will market the drug on behalf of N.K.Curex.
The drug is an aldose reductase inhibitor, which prevevts injury to neurocytes by inhibiting intraneural accumulation of sorbitol caused by diabetes. It is expected to be effective for diabetic neuropathy.
The number of diabetic patients in Japan is estimated to be about 7,000,000 of whom about 1,000,000 are thought to suffer from diabetic neuropathy. In order to improve patient’s QOL, N.K.Curex is committed to doing its best to obtain the approval as soon as possible, and KAKEN will do its best to have the drug used by as many patients as possible.
Outline of N. K. Curex Co., Ltd.